111 related articles for article (PubMed ID: 38670563)
1. Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer.
Huang S; Sheng G; Lv Q; Li Y; Meng Q; Gao X; Shang Z
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38670563
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety.
Ni J; Cheng X; Chen J; Guo W; Dai Z
Onco Targets Ther; 2020; 13():9857-9863. PubMed ID: 33116571
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
Cui Q; Hu Y; Ma D; Liu H
Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
[TBL] [Abstract][Full Text] [Related]
4. A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study.
Liu G; Feng Y; Li J; Deng T; Yin A; Yan L; Zheng M; Xiong Y; Li J; Huang Y; Zhang C; Huang H; Wan T; Huang Q; Lin A; Jiang J; Kong B; Liu J
EClinicalMedicine; 2022 Dec; 54():101767. PubMed ID: 36583171
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center retrospective study.
Wu Y; Li P; Zhu Y; Zhang F; Su L; Ye Y; Huang Y; Zhang M
Am J Transl Res; 2023; 15(3):1973-1981. PubMed ID: 37056822
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
Zhang W; Deng P; Kong T; Zhang B; Qian F; Dong Y; Chen Y; Chen L; Liu D; Zhang Y; Yang H; Han B
Lung Cancer; 2022 Nov; 173():43-48. PubMed ID: 36116169
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report.
Sun L; Yang M; Zhang X; Li H; Wu L; Zhang Y; Cai S
Medicine (Baltimore); 2020 May; 99(20):e20053. PubMed ID: 32443311
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
Front Oncol; 2022; 12():894835. PubMed ID: 36203439
[TBL] [Abstract][Full Text] [Related]
10. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Liu C; Liao J; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Wang J
Thorac Cancer; 2022 May; 13(10):1463-1470. PubMed ID: 35388976
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study.
Shen W; Jing C; Tian W; Zhang W; Ren Y; Shan B; Wang H
Int J Gynecol Cancer; 2023 Nov; 33(11):1764-1770. PubMed ID: 37775281
[TBL] [Abstract][Full Text] [Related]
13. Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study.
Ding J; Leng Z; Gu H; Jing X; Song Y
Front Oncol; 2023; 13():1153131. PubMed ID: 37361601
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
Wu Y; Zhou X; Zhao W; Wang Q; Han Z; Wang L; Zhou W; Zhou T; Song H; Chen Y; Yang K; Shi L; Pan B; Guo R; Zhou G; Jiang F; Feng J; Shen B
Invest New Drugs; 2023 Dec; 41(6):825-833. PubMed ID: 37837490
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study.
Huang Q; Chu C; Tang J; Dai Z
J Cancer; 2020; 11(18):5353-5358. PubMed ID: 32742481
[No Abstract] [Full Text] [Related]
16. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
Deng P; Hu C; Chen C; Cao L; Gu Q; An J; Qin L; Li M; He B; Jiang J; Yang H
Cancer Med; 2022 Oct; 11(19):3563-3571. PubMed ID: 35526266
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer.
Nakka T; Goenka L; Dubashi B; Kayal S; Mathaiyan J; Barathi D; Krishnamoorthy N; Thumaty DB; Dahagama S; Ganesan P
Med Oncol; 2022 Sep; 39(12):233. PubMed ID: 36175588
[TBL] [Abstract][Full Text] [Related]
19. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
[TBL] [Abstract][Full Text] [Related]
20. Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study.
Dai YJ; Qiu YR; Lin JG; Dai YB; Su YX; Yamada T; Uematsu S; Xu TW
J Thorac Dis; 2023 Oct; 15(10):5680-5688. PubMed ID: 37969289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
